Immix Biopharma, Inc.

NasdaqCM:IMMX Stock Report

Market Cap: US$547.1m

Immix Biopharma Future Growth

Future criteria checks 0/6

Immix Biopharma is forecast to grow earnings and revenue by 56.8% and 53.6% per annum respectively. EPS is expected to grow by 59.2% per annum. Return on equity is forecast to be -43.8% in 3 years.

Key information

56.8%

Earnings growth rate

59.20%

EPS growth rate

Biotechs earnings growth24.7%
Revenue growth rate53.6%
Future return on equity-43.84%
Analyst coverage

Low

Last updated29 Apr 2026

Recent future growth updates

Recent updates

Analysis Article • Aug 13

We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 08

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Nov 11

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Aug 12

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 28

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. Indeed, Immix Biopharma ( NASDAQ:IMMX...
Analysis Article • Jul 12

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 29

We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Sep 13

Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 21

We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Earnings and Revenue Growth Forecasts

NasdaqCM:IMMX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028206-8-5N/A3
12/31/202756-45-53N/A4
12/31/2026N/A-43-39N/A4
12/31/2025N/A-29-25-24N/A
9/30/2025N/A-24-15-14N/A
6/30/2025N/A-23-13-13N/A
3/31/2025N/A-21-13-12N/A
12/31/2024N/A-22-16-15N/A
9/30/2024N/A-22-16-16N/A
6/30/2024N/A-19-15-15N/A
3/31/2024N/A-18-13-13N/A
12/31/2023N/A-15-11-11N/A
9/30/2023N/A-14-13-13N/A
6/30/2023N/A-11-11-11N/A
3/31/2023N/A-9-8-8N/A
12/31/2022N/A-8-7-7N/A
9/30/2022N/A-27-5-5N/A
6/30/2022N/A-26-3-3N/A
3/31/2022N/A-25-3-3N/A
12/31/2021N/A-24-2-2N/A
9/30/2021N/A-200N/A
6/30/2021N/A-200N/A
3/31/2021N/A-200N/A
12/31/2020N/A-100N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMMX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMMX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMMX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMMX is forecast to have no revenue next year.

High Growth Revenue: IMMX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IMMX is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/07 23:06
End of Day Share Price 2026/05/07 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immix Biopharma, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Reni BenjaminCitizens JMP Securities, LLC
Jyoti PrakashEdison Investment Research
Robert BurnsH.C. Wainwright & Co.